Mirtazapine in the treatment of mood and anxiety disorders

References

• de Boer T The pharmacologic profile of mirtazapine. j Clin. Porhiatry57\(Suppl. 4), 19–25 (1996).
   Google Scholar
• •Classic paper on mirtazapine's binding properties.
   Google Scholar
• de Boer T, Nefkens F, Van Helvoirt A. The a2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo. Eur. Pharmacol 253(1–2), 5–6 (1994).
   Google Scholar
• Nutt D. Mirtazapine: pharmacology in relation to adverse effects. Acta Porbiatr Scand. 391 (Supp0,31–37 (1997).
   Google Scholar
• Schule C, Baghai T, Goy J, Bidlingmaier M, Strasburger C, Laakmann G. The influence of mirtazapine on anterior pituitary hormone secretion in healthy male subjects. Porhopharmacology (Berl) 163(1), 95–101 (2002).
   PubMed Web of Science ®Google Scholar
• Delbressine LP, Vos RM. The clinical relevance of preclinical data: mirtazapine, a model compound. J. Clin. Psychopharmacol 17\(Suppl. 1), S29—S33 (1997).
   Google Scholar
• Sitsen JM, Mans FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug—drug interaction study in healthy male subjects. Eur. Clin. Pharmacol 56(5), 389–394 (2000).
   Google Scholar
• Anttila AK, Rasanen L, Leinonen EV. Ruvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold. Ann. Phatmacother 35(10), 1221–1223 (2001).
   Google Scholar
• Benkert O, Muller M, Szegedi A. An overview of the clinical efficacy of mirtazapine. Hum. Porhopharmacol 17\(Suppl. 1), 23–26 (2002).
   Google Scholar
• Leinonen E, Skarstein J, Behnke K, Agren H, Helsdingen JT. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Int. Clin. Psychopharmacol 14(6), 329-337(1999).
   Google Scholar
• Wheatley DP, van Moffaert M, Timmerman L, Kremer CM. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J. Clin. Ptychiatry59(6), 306–312 (1998).
   Google Scholar
• Richou H, Ruimy P, Charbaut J et al. A multicentre, double-blind, controlled efficacy and safety study of Org 3770. Hum. Ptychopharmacol. 10,263-271 (1995).
   Google Scholar
• Bruijn JA, Moleman P, Mulder PG eta]. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed inpatients. Ptychopharmacology 04127(3), 231–237 (1996).
   Google Scholar
• Gueffi JD, Ansseau M, Timmerman L, Korsgaard S. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J. Clin. Ptychopharmacol. 21(4), 425–431 (2001).
   Google Scholar
• Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J. Affect. Disond 34(3), 165–171 (1995).
   Google Scholar
• Vartiainen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. Eur. Neumpsychopharmacol. 4(2), 145–150 (1994).
   PubMed Web of Science ®Google Scholar
• Thase ME, Nierenberg AA, Keller MB, Panagides J. Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. j Clin. Ptychiatry 62 (10), 782–788 (2001).
   PubMed Web of Science ®Google Scholar
• Pinder RM, Zivkov M. Imipramine and mirtazapine are less effective than expected. Ptychopharmacology Merl). 129(3), 297–298 (1997).
   Google Scholar
• Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J. Clin. Bychiatry 61 (9), 656–663 (2000).
   Google Scholar
• Schatzberg AF, Kremer C, Rodrigues HE, Murphy GM Jr. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. A117. I Geriatr. Psychiatry10(5), 541–550 (2002)
   Google Scholar
• van Moffaert M, de Wilde J, Vereecken A etal Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int. Clin. Bychopharmacol. 10(1), 3–9 (1995).
   Google Scholar
• Fava M. Weight gain and antidepressants. Clin. Ptychiatry 61 (Suppl. 11), 37–41 (2000).
   Google Scholar
• •An important analysis of weight gain amongst antidepressant drugs.
   Google Scholar
• Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study. Int. Clin. fiychopharmacol. 13(2), 63–73 (1998).
   Google Scholar
• Schittecatte M, Dumont F, Machowski R et al. Mirtazapine but not fluvoxamine, normalizes the blunted REM sleep response to clonidine in depressed patients: implications for subsensitivity of a-(2)-adrenergic receptors in depression. Psychiatry Res. 109(1), 1–8 (2002).
   Google Scholar
• Radhakishun FS, van den Bos J, van der Heijden BC, Roes KC, O'Hanlon JF. Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dosing regimens. J. Clin. fiychopharmacol. 20(5), 531–537 (2000).
   Google Scholar
• Carpenter LL, Yasmin S, Price LH. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol. fiychiatry 51 (2), 183–188 (2002).
   Google Scholar
• Ribeiro L, Busnello JV, Kauer-Sant'Anna M eta]. Mirtazapine versus fluoxetine in thetreatment of panic disorder. Braz. J. Med. Biol. Res. 34(10), 1303–1307 (2001).
   Google Scholar
• Bahk WM, Pae CU, Tsoh J eta]. Effects of mirtazapine in patients with post-traumatic stress disorder in Korea: a pilot study. Hum. fiychopharmacol. 17(7), 341–344 (2002).
   Google Scholar
• Koran LM, Quirk T, Lorberbaum JP, Elliott M. Mirtazapine treatment of obsessive—compulsive disorder. J. Clin. fiychopharmacol. 21(5), 537–539 (2001).
   Google Scholar
• Dunner DL, Hendrickson HE, Bea C, Budech CB, O'Connor E. Dysthymic disorder: treatment with mirtazapine. Depress. Anxiety10(2), 68–72 (1999).
   Google Scholar
• Davidson JR, Weisler RII, Butterfield MI eta]. Mirtazapine vs. placebo in post-traumatic stress disorder: a pilot trial. Biol. fiychiatry53(2), 188–191 (2003).
   Google Scholar
• Posey DJ, Guenin KD, Kohn AE, Swiezy NB, McDougle CJ. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J. Child Adolesc. Psychopharmacall (3), 267–277 (2001).
   Google Scholar
• Theobald DE, Kirsh KL, Holtsclaw E, Donaghy K, Passik SD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J. Pain Symptom Manabr. 23(5), 442–447 (2002).
   Google Scholar
• Nierenberg AA, Wright EC. Evolution of remission as the new standard in the treatment of depression. J. Clin. Psychiatry 60\(Suppl. 22), 7–11 (1999).
   Google Scholar
• ••Especially interesting as it addresses howto understand the clinical relevance of drug trials.
   Google Scholar
• Lerer B, Macciardi E Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. int. J. Neumpsychopharmacol. 5(3), 255–275 (2002).
   Google Scholar
• Yu YVV, Tsai SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. MoL Psychiatry 7(10), 1115–1119 (2002).
   PubMed Web of Science ®Google Scholar
• Bremner JD. A double-blind comparison of Org 3770, amitriptyline and placebo in major depression.' Clin. Ptychiatry56(11), 519–525 (1995).
   Google Scholar
• Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Ptychopharmacol. Buli. 26(2), 191–196 (1990).
   Google Scholar
• Stahl S, Zivkov M, Reimitz PE, Panagides J, Hoff W Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr Scant/. 391 (Suppl.), 22–30 (1997).
   Google Scholar
• Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 7(3), 249–264 (2001).
   PubMedGoogle Scholar
• Haddjeri N, Blier P, de Montigny C. Effects of long-term treatment with the a-2-adrenoceptor antagonist mirtazapine on 5-HT neurotransmission. Naunyn Schmiedebergs Arrh. Pharmacol. 355(1), 20–29 (1997).
   Google Scholar
• Haddjeri N, Blier P, de Montigny C. Long- term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. Neurosci. 18(23), 10150–10156 (1998).
   Google Scholar
• Thome J, Henn FA, Duman RS. Cyclic AMP response element-binding protein and depression. Expert Rev Neurotherapeutics 2 (3), 347–354 (2002) .
   PubMedGoogle Scholar
• •A timely, well written review of this cellular mechanism of antidepressant response.
   Google Scholar
• Timmer CJ, Sitsen JM, Delbressine LP Clinical pharmacokinetics of mirtazapine. Clin. Pharmacokinet. 38(6),461–474 (2000).
   PubMed Web of Science ®Google Scholar
• Marttila M, Jaaskelainen J, Jarvi R etal A double-blind study comparing the efficacy and tolerability of mirtazapine and doxepin in patients with major depression. Eur Neuropsychophatmacol 5(4), 441–446 (1995).
   PubMed Web of Science ®Google Scholar